A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues

References

• Rossi G. Phrophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBs Ag carriers with hematooncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003; 44: 759–766
   PubMed Web of Science ®Google Scholar
• Yađcý M, Sucak G T, Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. Am J Hematol 2000; 64: 233–234
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58–62
   PubMed Web of Science ®Google Scholar
• Haznedar R, Yađcý M. Lamivudine therapy for acute hepatitis B infection following peripheral blood stem cell transplantation. Am J Hematol 2002; 69: 151
   PubMed Web of Science ®Google Scholar
• Liao C A, Lee C M, Wu H C, Wang M C, Lu S N, Eng H L. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002; 116: 166–169
   PubMed Web of Science ®Google Scholar
• Lai C L, Chien R N, Leung N W, Chang T T, Guan R, Tai D I, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–68
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987 – 1991. Cancer 1996; 78: 2210–2215
   PubMed Web of Science ®Google Scholar
• Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 2925–2930
   PubMed Web of Science ®Google Scholar
• Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Annals of Oncology 1997; 8(Suppl 1)107–109
   PubMed Web of Science ®Google Scholar
• Persico M, De Marino F, Russo G D, Morante A, Rotoli B, Torella R, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99: 724–725
   PubMed Web of Science ®Google Scholar
• Lau G K, Liang R, Wu P C, Lee C K, Lim W L, Au W Y. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998; 28: 359–368
   PubMed Web of Science ®Google Scholar
• Ahmed A, Keeffe E B. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249–251
   PubMed Web of Science ®Google Scholar
• Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391–396
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan P K, Ho W M, Zee B, Lam K C, Lei K I, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927–934
   PubMed Web of Science ®Google Scholar
• Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000; 108: 394–396
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan P K, Zhong S, Ho W M, Steinberg J L, Tam J S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307
   PubMed Web of Science ®Google Scholar
• Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296–1303
   PubMed Web of Science ®Google Scholar
• Cheng A L, Hsiung C A, Su I J, Chen P J, Chang M C, Tsao C J, et al. Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320–1328
   PubMed Web of Science ®Google Scholar
• Yeo W, Zee B, Zhong S, Chan P K, Wong W L, Ho W M, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306–1311
   PubMed Web of Science ®Google Scholar
• Yavuz S, Paydaş S, Disel U, Şahin B. Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1249–1250
   PubMed Web of Science ®Google Scholar
• Dai M S, Chao T Y, Kao W Y, Shyu R Y, Liu T M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769–774
   PubMed Web of Science ®Google Scholar